Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant-Reference-Cited by-同舟云学术

Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant

Published:2019-08-02 Issue:14 Volume:8 Page:6212-6220
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

He Min¹,Li Jun‐Jie¹,Zuo Wen‐Jia¹,Ji Lei²,Jiang Yi‐Zhou¹,Hu Xi‐Chun²,Wang Zhong‐Hua¹,Shao Zhi‐Ming¹^ORCID

Affiliation:

1. Key Laboratory of Breast Cancer, Department of Breast Surgery Fudan University Shanghai Cancer Center, Shanghai Medical College Fudan University Shanghai China

2. Department of Oncology Fudan University Shanghai Cancer Center, Shanghai Medical College Fudan University Shanghai China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2453

Reference19 articles.

1. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome

2. Correction to: 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

3. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

4. Palbociclib and Letrozole in Advanced Breast Cancer

5. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a prognostic model for lung adenocarcinoma polarity‐related genes and analysis of immune landscape;Biotechnology and Applied Biochemistry;2024-03-12

2. Recent progress of CDK4/6 inhibitors’ current practice in breast cancer;Cancer Gene Therapy;2024-02-26

3. Blocking tumor-platelet crosstalk to prevent tumor metastasis via reprograming glycolysis using biomimetic membrane-hybridized liposomes;Journal of Controlled Release;2024-02

4. Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical Practice;Cancers;2023-11-02

5. Survival impact of fulvestrant-based combination therapies in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer with liver metastasis: a case-control study;2023-08-24